Autoplaque vs Zio AT ECG Monitoring System

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Autoplaque

by APQ Health (formerly Cedars-Sinai Medical Center: AIM)

Zio AT ECG Monitoring System

by iRhythm Technologies, Inc.

AI Verdict

Autoplaque and Zio AT are adjacent tools in cardiology, both leveraging AI but for distinct purposes. Autoplaque focuses on the quantitative analysis of coronary plaques and luminal stenoses from CT angiography images to predict heart attack risk, providing detailed anatomical insights. Zio AT, conversely, is a wearable ECG monitoring system designed for continuous, long-term arrhythmia detection and reporting, focusing on electrical activity of the heart.

Choose Autoplaque if…

Choose Autoplaque if you need an AI-powered, workstation-based solution for detailed quantitative analysis of coronary plaques and luminal stenoses from CT angiography images. This tool is ideal for cardiologists and radiologists seeking to assess heart attack risk and guide treatment plans through precise measurements of coronary anatomy and pathology.

View Autoplaque →

Choose Zio AT ECG Monitoring System if…

Choose Zio AT ECG Monitoring System if you require continuous, long-term (up to 14 days) AI-powered ECG monitoring for arrhythmia detection in an outpatient setting. This wearable, cloud-based system is best suited for identifying symptomatic and asymptomatic cardiac events, providing comprehensive reports for clinicians, and managing patients remotely.

View Zio AT ECG Monitoring System →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Autoplaque	Zio AT ECG Monitoring System
Pricing	Unknown	Contact for pricing
Deployment	Workstation-based post-processing application, runs on Windows or Mac OS.	Cloud-based (data analytics and clinician portal)
FDA Status	1 AI-estimated	1 AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio AT ECG Monitoring System

Autoplaque is workstation-based software for trained medical professionals, requiring installation and specific hardware. Zio AT, a wearable patch with a mobile app, is designed for patient self-application and continuous monitoring during daily activities, including showering, offering greater convenience and ease of use for the patient.

Clinical Value

Tie

Both tools are FDA-cleared and offer significant clinical value in their respective domains. Autoplaque provides AI-powered quantitative analysis of coronary plaques and luminal stenoses from CT angiography, aiding in heart attack risk prediction and treatment guidance, validated in over 100 published studies. Zio AT offers continuous, AI-powered ECG monitoring for long-term arrhythmia detection, with over 100 scientific manuscripts demonstrating its value and a 99% physician agreement rate on reports.

Pricing & Value

Zio AT ECG Monitoring System

Autoplaque's pricing is not disclosed. Zio AT's pricing is not publicly disclosed but iRhythm Technologies offers various payment options, including financial assistance, self-pay pricing, and installment plans, and states that the service is covered by most major commercial insurance providers and Medicare, demonstrating a more transparent and accessible approach to cost for patients.

Enterprise Readiness

Zio AT ECG Monitoring System

Zio AT is a cloud-based solution with a clinician portal and mobile app, facilitating patient management and report interpretation across an enterprise. It also emphasizes HIPAA compliance and has a Business Associate Agreement (BAA). Autoplaque is workstation-based software, which may present more challenges for large-scale enterprise deployment and integration, and its HIPAA compliance and BAA status are not specified.

Innovation

Tie

Autoplaque represents innovation in cardiac imaging by using AI for quantitative analysis of coronary plaque, shifting the paradigm from just measuring stenosis to assessing plaque volume for heart attack risk. Zio AT innovates in remote cardiac monitoring with its wearable patch, continuous recording for up to 14 days, and AI-powered arrhythmia detection, offering a significant advancement over traditional Holter monitors.

Support & Docs

Zio AT ECG Monitoring System

Zio AT provides a MyZio patient mobile app for symptom logging and education, and iRhythm offers a 24/7 customer service team for troubleshooting patient-related issues. While Autoplaque is supported by Cedars-Sinai, specific details on user support and documentation beyond its intended use by trained medical professionals are not readily available in the provided information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Autoplaque	Zio AT ECG Monitoring System
Name	Autoplaque	Zio AT ECG Monitoring System
Company	Cedars-Sinai Medical Center: AIM	iRhythm Technologies, Inc.
Description	Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance.	The Zio AT ECG Monitoring System by iRhythm Technologies is an FDA-cleared, wearable mobile cardiac telemetry (MCT) service offering continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting.
Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI, Wearables & Remote Monitoring (RPM)
Key Features (AI/Analysis Focus)	AI-powered quantitative analysis of atherosclerotic plaque, Detection and characterization of coronary artery plaque, Measurement of luminal stenoses	FDA-cleared deep-learned AI algorithm (ZEUS System) for arrhythmia detection, Continuous, uninterrupted ECG recording for up to 14 days, Detection of symptomatic and asymptomatic cardiac events

Videos

Demos, reviews, and walkthroughs featuring Autoplaque and Zio AT ECG Monitoring System.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows for cardiologists and radiologists?

Autoplaque is a workstation-based post-processing application designed for cardiologists and radiologists to view and analyze cardiac CT data, functioning as an interactive tool within the CCTA workflow. Zio AT, on the other hand, is a mobile cardiac telemetry service that integrates with EHR systems, allowing for streamlined ordering, patient registration, and electronic delivery of end-of-wear reports directly into the EHR.

What is the accuracy and sensitivity of each tool in detecting and characterizing cardiac conditions?

Autoplaque demonstrates excellent correlation with intravascular ultrasound (IVUS) for quantifying noncalcified plaque volumes (r = 0.94, P < .001) and calcified plaque, and has been validated in multicenter studies. The Zio AT system utilizes an FDA-cleared deep-learned AI algorithm for arrhythmia detection, with physicians agreeing with 99% of the comprehensive end-of-wear reports. Studies show Zio monitors have a higher diagnostic yield for arrhythmias compared to traditional Holter monitoring, with detection rates increasing with longer wear times.

What is the typical learning curve for physicians to effectively use each tool?

Autoplaque is intended for use by trained medical professionals, including radiologists and cardiologists, who have been appropriately trained in its functions, capabilities, and limitations. The Zio AT system is designed for ease of use, with the Zio patch being a simple 'peel and stick' application for patients, and the ZioSuite clinician portal aiming to simplify workflows for healthcare professionals.

What kind of customer support and resources are available for each tool?

For Zio AT, iRhythm provides a ZioSuite clinician portal and mobile app for patient management and report interpretation, along with a MyZio patient mobile app for symptom logging and education. Customer care is also available for questions regarding the Zio AT patch or gateway and for accessing additional patient data during the wear period.

Are there audit-trail features available to track usage and data access for clinical and administrative purposes?

While the provided information does not explicitly detail audit-trail features for Autoplaque, the Zio AT system integrates with EHRs, and its cloud-based nature for data analytics and clinician portal would typically incorporate robust logging for data access and changes, though specific audit-trail features are not detailed in the provided text.

What clinical context would help a physician choose between Autoplaque and Zio AT?

A physician would choose Autoplaque for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images to aid in heart attack risk prediction and treatment guidance. Zio AT would be chosen for continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting, particularly for patients with transient symptoms or infrequent arrhythmias that might be missed by shorter monitoring periods.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Autoplaque or Zio AT ECG Monitoring System

Backers

Who funded each tool's parent company.